Continuing Treatment for Subjects Who Have Participated on a Prior Protocol Investigating Dasatinib
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 20 Jul 2017
At a glance
- Drugs Dasatinib (Primary)
- Indications Cancer; Chronic myeloid leukaemia; Prostate cancer
- Focus Therapeutic Use
- Sponsors Bristol-Myers Squibb
- 17 Jul 2017 Planned End Date changed from 30 Dec 2018 to 28 Feb 2018.
- 17 Jul 2017 Planned primary completion date changed from 30 Dec 2018 to 27 Feb 2018.
- 08 Nov 2016 Status changed from recruiting to active, no longer recruiting.